Breast Cancer

Dr. Erika Hamilton on VERITAC-2: Vepdegestrant Shows PFS Benefit in ESR1m ER+/HER2- Breast Cancer
Dr. Erika Hamilton on VERITAC-2: Vepdegestrant Shows PFS Benefit in ESR1m ER+/HER2- Breast Cancer
Erika P. Hamilton, MDHR Breast Cancer | June 5, 2025
Vepdegestrant improves PFS in ESR1-mutant ER+/HER2- breast cancer, offering a well-tolerated oral option post-CDK4/6.
ASCENT-04/KEYNOTE-D19 Supports Sacituzumab Govitecan Plus Pembrolizumab As New Standard of Care in Advanced PD-L1–Positive TNBC
ASCENT-04/KEYNOTE-D19 Supports Sacituzumab Govitecan Plus Pembrolizumab As New Standard of Care in Advanced PD-L1–Positive TNBC
Lauren Dembeck, PhDTriple-Negative Breast Cancer | June 4, 2025
Sacituzumab + pembrolizumab improves PFS vs chemo in PD-L1+ TNBC, per ASCENT-04/KEYNOTE-D19 phase 3 trial at ASCO 2025.
DESTINY-Breast09: Will T-DXd + Pertuzumab Replace THP in First-Line HER2+ mBC?
DESTINY-Breast09: Will T-DXd + Pertuzumab Replace THP in First-Line HER2+ mBC?
Maryam Lustberg, MD, MPHHER2 Breast Cancer | June 4, 2025
Dr. Lustberg discusses DESTINY-Breast09 and the potential shift to T-DXd + pertuzumab in HER2+ mBC first-line treatment.
Dr. Stephanie Graff’s Top 3 Breast Cancer Abstracts from ASCO 2025
Dr. Stephanie Graff’s Top 3 Breast Cancer Abstracts from ASCO 2025
Stephanie L. Graff, MDHER2 Breast Cancer | June 4, 2025
Stephanie Graff, MD, reviews top ASCO25 breast cancer trials, including ASCENT-04, DESTINY-Breast09, and SERENA-6.
Dr. Gradishar on Managing Toxicities and Tailoring Treatment in HER2+ mBC
Dr. Gradishar on Managing Toxicities and Tailoring Treatment in HER2+ mBC
William J. Gradishar, MDHER2 Breast Cancer | June 4, 2025
Dr. Gradishar discusses how tolerability, toxicity, and NCCN guidelines shape HER2+ breast cancer treatment decisions.
Sequencing HER2-Targeted Therapies: What Comes After THP?
Sequencing HER2-Targeted Therapies: What Comes After THP?
William J. Gradishar, MDHER2 Breast Cancer | June 4, 2025
Dr. William Gradishar discusses treatment sequencing strategies for HER2+ metastatic breast cancer at ASCO 2025.
DESTINY-Breast09: T-DXd Plus Pertuzumab Boosts PFS in HER2+ mBC
DESTINY-Breast09: T-DXd Plus Pertuzumab Boosts PFS in HER2+ mBC
Yvette C. TerrieHER2 Breast Cancer | June 3, 2025
T-DXd plus pertuzumab significantly improves PFS vs THP in HER2+ mBC, per interim results from DESTINY-Breast09.
Elinzanetant Eases Vasomotor Symptoms in HR+ Breast Cancer
Elinzanetant Eases Vasomotor Symptoms in HR+ Breast Cancer
Lauren Dembeck, PhDHR Breast Cancer | June 3, 2025
Elinzanetant reduces vasomotor symptoms from endocrine therapy in HR+ breast cancer, with rapid onset and good tolerability.
NeoCARHP: THP Non-Inferior to TCbHP, With Better Tolerability
NeoCARHP: THP Non-Inferior to TCbHP, With Better Tolerability
Yvette C. TerrieHER2 Breast Cancer | June 3, 2025
THP delivers similar pCR and better tolerability than TCbHP for HER2+ early breast cancer, per phase 3 neoCARHP trial.
AI-Based TIL Analysis Predicts pCR in HR+/HER2– Breast Cancer
AI-Based TIL Analysis Predicts pCR in HR+/HER2– Breast Cancer
Yvette C. TerrieHR Breast Cancer | June 2, 2025
AI-powered TIL analysis may predict pCR and survival outcomes in HR+/HER2– breast cancer treated with neoadjuvant chemo.
Advertisement

Expert Interviews on Oncology

Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Editorial Policy

    Advertising

    Connect

    Contact Us

    eNewsletters

    Contribute

    Career Center

    Our Network

    MashupMD

    Blood Cancers Today

    Cancer Nursing Today

    GU Oncology Now

    Urban Health Today

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |